Mislabeled Citalopram, Finasteride Tablets Recalled

A potentially dangerous case of switched medications has been announced by the U.S. Food and Drug Administration (FDA), which said that Greenstone LLC has issued a <"http://www.yourlawyer.com/practice_areas/defective_drugs">drug recall, down to the patient level, of medicines with lot number FI0510058-A on the label.

This recall includes Citalopram 10mg Tablets (100-count bottle) and Finasteride 5mg Tablets (90-count bottle), which were both distributed in the U.S. market. The recall was called because a third-party manufacturer may have placed incorrect labels on the bottles.

This is the only lot number being recalled and no other lots or markets are believed to be impacted.

Bottles of either Citalopram (used to treat depression) or Finasteride (for the treatment of benign prostatic hyperplasia) with lot number FI050058-A should be returned to the pharmacist.

Bottles labeled as Citalopram Lot # FI0510058-A may contain Finasteride. Patients who believe they may have ingested the wrong medication should contact their physician as soon as possible. Women who are, or may become pregnant, should not take or handle Finasteride due to the possible risk of side effects which may cause abnormalities to the external genitalia of a developing male fetus.

Citalopram is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or pimozide and is also contraindicated in patients with a hypersensitivity to Citalopram or any of the inactive ingredients in the tablet. Patients who discontinue Citalopram abruptly by inadvertently taking the mislabeled product may experience discontinuation symptoms and/or worsening of depression.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this recalled product. Also, any adverse events that may be related to the use of these products should be reported to Pfizer Inc. at-1-800-438-1985 24 hours a day (Greenstone LLC is a wholly owned subsidiary of Pfizer Inc.) or to FDA’s Med Watch Program either online, by regular mail, or by fax:

• Online: www.fda.gov/medwatch/report.htm1

• Regular Mail: Use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm2. Mail to the address on the pre-addressed form.

• Fax: 1-800-FDA-0178

This entry was posted in Pharmaceuticals. Bookmark the permalink.

© 2005-2020 Parker Waichman LLP ®. All Rights Reserved.